Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods
US10456404B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 14, 2016 |
| Grant date | Oct 29, 2019 |
| Priority date | — |
| Expiry date | Mar 14, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/347
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein is the identification of cGMP-specific phosphodiesterase upregulation in cystic kidney diseases. Also described is the use of cGMP-specific phosphodiesterase inhibitors for preventing the progression and/or treatment of cystic kidney diseases. Other aspects described provide medicaments for preventing the progression and/or treating cystic kidney diseases, and methods of diagnosing cystic kidney disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.